Title: CIRCULATING TUMOR CELLS (CTCs) AS A MARKER OF THE RADICALITY OF SURGICAL TREATMENT OF BREAST CANCER

Biography:

medical and surgical oncology, molecular oncology, cancer genetics, personalized therapy for malignant tumors.

He is the author of more than 100 scientific papers, including one monograph, 6 patents for invention, 3 instructions for use. He is the developer of four unique test systems for the diagnosis of minimal residual disease in solid tumors. He was a project manager and executive in charge of the international project LLB-2-242 «Improving the quality of medical care through the use of information technologies for the diagnosis of skin cancer and lung cancer (Lithuania-Latvia-Belarus 2012–2015)». The direct scientific leadership, such scientific programs of the Belarusian Republican Foundation for Basic Research as «Breast Cancer and Epstein-Barr Viral Infection» (2013–2015), «Molecular Genetic Diagnosis of Minimal Residual Disease in Breast Cancer» (2015–2017) , the scientific theme of the State program of scientific research «Assess the expression of tumor progression genes in order to identify the minimum residual disease in breast cancer» (2016–2017).

At present, Yauheni A Shliakhtunou is the scientific director of the research topic «To study the prognostic and predictive significance of miRNA expression in circulating tumor cells in patients suffering from breast cancer with overexpression of the epidermal growth factor receptor Her2-neu» (2019–2020).

Abstract

To determine the clinical significance of circulating tumor cells expressing the targeted genes BIRC5 and HER2-neu - markers of minimal residual disease, as markers of the "purity" of the surgical stage of breast cancer treatment,

The study involved 230 patients with verified primary non-metastatic breast cancer (BC) stage I-IIIC at the age of 58.2 ± 9.9 years. All women underwent surgery in the amount of radical mastectomy in Madden (group 1) – 113 (49.1%), oncoplastic radical resection of the breast (group 2) – 49 (21.3%), and 68 (29.6%) women underwent bilateral subcutaneous mastectomy with regional lymph node dissection on the affected side with simultaneous implant reconstruction (group 3). In all patients on the day of surgery, as well as on day 2 after surgery, peripheral blood was examined for the presence of circulating tumor cells (CTCs). To identify the CTCs, the expression of the BIRC5 and HER2-neu genes was studied using real-time PCR.